Impedimed Valuation Multiples

Impedimed Overview

About Impedimed

Impedimed Ltd, together with its subsidiaries, operates in the medical devices space. The company is based in Australia and operates globally, and it generates the majority of its revenue in North America. It is engaged in developing, manufacturing, and distributing noninvasive medical devices. The company offers products that are typically used to assess and monitor lymphedema and heart failure, as well as to measure the tissue composition and fluid status of the patients. The company also offers a cloud-based digital platform (branded as SOZO) to manage patient data. The company recognises revenue from the stand-alone sale of Legacy Devices and Consumables, the Sale of SOZO Devices, and Software Subscription Services.

Founded

1999

HQ

Employees

77

Website

impedimed.com

Sectors

Health Data & AnalyticsMedical DevicesDeepTechHealthTech

Financials (LTM)

Revenue: $11M

EBITDA: ($11M)

EV

$26M

Valuation Multiples

Multiples.vc

Start free trial

Impedimed Financials

Impedimed reported last 12-month revenue of $11M and negative EBITDA of ($11M).

In the same LTM period, Impedimed generated ($11M) in EBITDA losses and had net loss of ($14M).

Impedimed P&L

In the most recent fiscal year, Impedimed reported revenue of $9M and EBITDA of ($12M).

Impedimed expects next 12-month revenue of XXX and NTM EBITDA of XXX

Impedimed Stock Performance

Impedimed has current market cap of $25M, and enterprise value of $26M.

Impedimed's stock price is $0.01.

Impedimed Valuation Multiples

Impedimed trades at 2.5x EV/Revenue multiple, and (2.4x) EV/EBITDA.

Impedimed Financial Valuation Multiples

As of March 14, 2026, Impedimed has market cap of $25M and EV of $26M.

Equity research analysts estimate Impedimed's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Impedimed has a P/E ratio of (1.7x).

Impedimed Margins & Growth Rates

Impedimed's revenue in the last 12 month grew by 39%.

Impedimed's revenue per employee in the last FY averaged $0.1M.

Impedimed's rule of 40 is (64%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Impedimed's rule of X is (6%) (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Impedimed Public Comps

See public comps and valuation multiples for other Health Data & Analytics and Medical Devices comps.

Impedimed M&A Activity

Impedimed acquired XXX companies to date.

Last acquisition by Impedimed was on XXXXXXXX, XXXXX. Impedimed acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

Impedimed Investment Activity

Impedimed invested in XXX companies to date.

Impedimed made its latest investment on XXXXXXXX, XXXXX. Impedimed invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).